C. difficile infections generate an annual economic burden of more than $1 billion. Traditional first line treatment includes antibiotics. Researchers found FMT to be more cost-effective than metronidazole and fidaxomicin.
The researchers concluded that C. difficile infection treatment guidelines should consider recommending use of FMT at an earlier time.
More Articles on Gastroenterology:
6 Statistics on Colorectal Cancer Diagnosis & Mortality
2014 Outlook: 7 Issues for Gastroenterologists to Focus on This Year
5 Things to Know About Advances in Oral Treatment for Hepatitis C
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
